Azenta, Inc. $AZTA Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC increased its holdings in Azenta, Inc. (NASDAQ:AZTA) by 16.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,613,914 shares of the company’s stock after purchasing an additional 225,867 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Azenta were worth $34,183,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Assetmark Inc. increased its stake in shares of Azenta by 54.1% during the 4th quarter. Assetmark Inc. now owns 832 shares of the company’s stock valued at $28,000 after acquiring an additional 292 shares during the last quarter. Osaic Holdings Inc. boosted its holdings in shares of Azenta by 44.9% in the 2nd quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock valued at $39,000 after purchasing an additional 385 shares during the last quarter. CWM LLC boosted its holdings in Azenta by 27.3% in the fourth quarter. CWM LLC now owns 1,822 shares of the company’s stock valued at $61,000 after acquiring an additional 391 shares during the last quarter. Empowered Funds LLC lifted its stake in shares of Azenta by 10.5% in the 1st quarter. Empowered Funds LLC now owns 6,482 shares of the company’s stock valued at $225,000 after purchasing an additional 618 shares in the last quarter. Finally, Neuberger Berman Group LLC lifted its holdings in shares of Azenta by 8.9% during the 4th quarter. Neuberger Berman Group LLC now owns 8,379 shares of the company’s stock valued at $279,000 after acquiring an additional 684 shares in the last quarter. Hedge funds and other institutional investors own 99.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Needham & Company LLC decreased their price target on shares of Azenta from $44.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Weiss Ratings raised shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Azenta presently has a consensus rating of “Hold” and a consensus price target of $39.50.

Azenta Stock Performance

AZTA stock opened at $26.29 on Monday. The firm has a market cap of $1.21 billion, a P/E ratio of -6.64 and a beta of 1.37. Azenta, Inc. has a 12-month low of $15.93 and a 12-month high of $41.73. The stock’s 50 day simple moving average is $22.68 and its 200 day simple moving average is $26.29.

Azenta (NASDAQ:AZTA) last issued its earnings results on Wednesday, May 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.16). The business had revenue of $144.79 million during the quarter, compared to the consensus estimate of $148.47 million. Azenta had a positive return on equity of 1.23% and a negative net margin of 30.49%.The business’s revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.01 EPS.

Azenta Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.